iPubs - Gavreto - Live Broadcast

From: <Rep Name> <edigest@contagionlive.com>
Sent: <Variable Day of week, Month day, 2020 Time AM or PM>
To: <Variable attendee email address>
Subject: Live Broadcast Invitation: Retooling Tetracyclines for 21st Century Challenges

No Images? Click here

This promotional program is sponsored by Paratek Pharmaceuticals, Inc and it is not eligible for continuing medical education credits.

LIVE BROADCAST

Join us to learn about GAVRETO^™ (pralsetinib)

INDICATION

GAVRETO^™ (pralsetinib) is a kinase inhibitor indicated for the treatment of patients with rearranged during transfection (RET)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) as detected by an FDA approved test. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and confirmation of clinical benefit in a confirmatory trial(s).

In this Live Broadcast, [Speaker #1 and Speaker #2] will:

Explore data from GAVRETO clinical trials

Review important safety information of GAVRETO

Present a real-world patient case from identification to management

Faculty information

Kerry Laplante, PharmD, FCCP, FIDSA

Professor of Pharmacy
University of Rhode Island
Kingston, RI

Adjunct Professor of Medicine
Brown University
Providence, RI

Director of the Rhode Island Infectious Diseases Fellowship and Research Programs
Veterans Affairs Medical Center
Providence, RI

Abhay Dhand, MD

Director, Transplant Infectious Diseases
Westchester Medical Center
Valhalla, NY

Associate Professor of Medicine
New York Medical College
Valhalla, NY

VIEW LIVE BROADCAST